Vicore Pharma completes enrolment of the global Phase 2b ASPIRE trial evaluating buloxibutid in idiopathic pulmonary fibrosis with topline results are expected in mid-2027 - Meet them in September
Calluna Pharma completes enrolment six months ahead of schedule for its global Phase 2 AURORA study of CAL101 for idiopathic pulmonary fibrosis with topline results are expected in Q1 2027
Chairs’ Recap of the Track Sessions: Coming Together Across the Therapeutic Development Stages to Harness a Complete Picture of the Pulmonary Fibrosis Field
Chairs’ Recap of the Track Sessions: Coming Together Across the Therapeutic Development Stages to Harness a Complete Picture of the Pulmonary Fibrosis Field
